Reference Detail

Ref Type
Authors Sheng Yang, Jianliang Yang, Ying Han, Yan Qin, Xiaohong Han, Lihou Dong, Hui Feng, Haifeng Song, Yan Sun, Yuankai Shi
Title A phase 1 trial of JS001, a monoclonal antibody targeting programmed death-1 (PD-1) in patients with advanced or recurrent malignancies.
Abstract Text J Clin Oncol 35, 2017 (suppl; abstr e14581)


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Toripalimab Toripalimab 7 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
Toripalimab JS001|JS-001|TAB001 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 51 Toripalimab (JS001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (PMID: 28317872; J Clin Oncol 35, 2017 (suppl; abstr e14581)).
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Toripalimab Phase I Actionable In a Phase I clinical trial, JS001 demonstrated tolerability and preliminary efficacy in patients with advanced malignancies, resulting in complete response in 1/15, partial response in 5/15, and stable disease in 5/15 patients (J Clin Oncol 35, 2017 (suppl; abstr e14581)). detail...